SCHEMBL5099539

SCHEMBL5099539

O=c1c(Cl)c(Cl)cnn1CCN1CCOCC1

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTT P42858 10/20 0.63
RAB9A P51151 8/20 0.63
MITF O75030 7/20 0.63
LMNA P02545 5/20 0.63
NPC1 O15118 5/20 0.63
ALDH1A1 P00352 8/20 0.46
SMN1; SMN2 Q16637 6/20 0.46
NPSR1 Q6W5P4 4/20 0.46
POLB P06746 3/20 0.46
MEN1 O00255 3/20 0.46
KMT2A Q03164 3/20 0.46
BLM P54132 1/20 0.46
GPR35 Q9HC97 1/20 0.46
PKM P14618 1/20 0.46
MAPT P10636 4/20 0.44
RECQL P46063 3/20 0.44
S1PR4 O95977 3/20 0.43
S1PR1 P21453 3/20 0.43
CNR1 P21554 2/20 0.43
CNR2 P34972 2/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL5103337 0.98 HTT (0.61) HTTRAB9AMITFLMNANPC1
SCHEMBL5103228 0.77 ADORA2A (0.44) HTTRAB9AMITFLMNANPC1
SCHEMBL14574536 0.77 HTT (0.56) HTTRAB9AMITFLMNANPC1
Hydrochloric Acid SCHEMBL5098239 0.76 ADORA2A (0.43) HTTRAB9AMITFLMNANPC1
SCHEMBL9673808 0.75 NPC1 (0.51) HTTRAB9AMITFLMNANPC1
SCHEMBL10360715 0.75 HTT (0.54) HTTRAB9AMITFLMNANPC1
SCHEMBL28854385 0.75 SIGMAR1 (0.43) POLBKMT2ASIGMAR1CYP3A4CYP2C19
SCHEMBL9234092 0.74 HTT (0.57) HTTRAB9AMITFLMNANPC1
SCHEMBL10884770 0.74 HTT (0.53) HTTRAB9AMITFLMNANPC1
SCHEMBL9763242 0.74 HTT (0.55) HTTRAB9AMITFLMNANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080004270-A1 3,4-Disubstituted Pyrazoles as Cyclin Dependent Kinases (Cdk) or Aurora Kinase or Glycogen Synthase 3 (Gsk-3) Inhibitors ASTEX THERAPEUTICS LIMITED (UK) 2008-01-03 US disclosed
US-20080004270-A1 3,4-Disubstituted Pyrazoles as Cyclin Dependent Kinases (Cdk) or Aurora Kinase or Glycogen Synthase 3 (Gsk-3) Inhibitors ASTEX THERAPEUTICS LIMITED (UK) 2008-01-03 US disclosed
US-20080004270-A1 3,4-Disubstituted Pyrazoles as Cyclin Dependent Kinases (Cdk) or Aurora Kinase or Glycogen Synthase 3 (Gsk-3) Inhibitors ASTEX THERAPEUTICS LIMITED (UK) 2008-01-03 US disclosed
EP-1781653-A1 3,4-DISUBSTITUTED PYRAZOLES AS CYCLIN DEPENDENT KINASES (CDK) OR AURORA KINASE OR GLYCOGEN SYNTHASE 3 (GSK-3) INHIBITORS Astex Therapeutics Limited (GB) 2007-05-09 EP disclosed
WO-2006003440-A1 3,4-DISUBSTITUTED PYRAZOLES AS CYCLIN DEPENDENT KINASES (CDK) OR AURORA KINASE OR GLYCOGEN SYNTHASE 3 (GSK-3) INHIBITORS ASTEX THERAPEUTICS LIMITED (GB) 2006-01-12 WO disclosed
WO-2006003440-A1 3,4-DISUBSTITUTED PYRAZOLES AS CYCLIN DEPENDENT KINASES (CDK) OR AURORA KINASE OR GLYCOGEN SYNTHASE 3 (GSK-3) INHIBITORS ASTEX THERAPEUTICS LIMITED (GB) 2006-01-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080004270-A1 3,4-Disubstituted Pyrazoles as Cyclin Dependent Kinases (Cdk) or Aurora Kinase or Glycogen Synthase 3 (Gsk-3) Inhibitors CDK3, CDK1, GSK3B HTT 4462/4885RAB9A 3974/4885MITF 3761/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.